Outcome of Treatment in Children with Philadelphia ChromosomePositive Acute Lymphoblastic Leukemia
Maurizio Aricò, M.D., Maria Grazia Valsecchi, Ph.D., Bruce Camitta, M.D., Martin Schrappe, M.D., Judith Chessells, M.D., André Baruchel, M.D., Paul Gaynon, M.D., Lewis Silverman, M.D., Gritta Janka-Schaub, M.D., Willem Kamps, M.D., Ching-Hon Pui, M.D., Giuseppe Masera, M.D., V. Conter, M.D., H. Riehm, M.D., N. Heerema, Ph.D., S. Sallan, M.D., J. Pullen, M.D., J. Shuster, Ph.D., A. Carroll, Ph.D., S. Raimondi, Ph.D., and S. Richards, M.D.
Background Children with Philadelphia chromosomepositiveacute lymphoblastic leukemia (Ph-positive ALL) have a poor prognosis,and there is no consensus on the optimal treatment for thisvariant of ALL.
Methods We reviewed the medical records of patients with Ph-positiveALL who were treated with intensive chemotherapy, with or withoutbone marrow transplantation, by 10 study groups or large singleinstitutions from 1986 to 1996. Data on 326 children and youngadults, who ranged in age from 0.4 to 19.9 years (median, 8.1),were analyzed to determine the rate of complete remission andthe probability of event-free, disease-free, and overall survivalaccording to standard prognostic factors and type of treatment.
Results The 267 patients who had a complete remission afterinduction chemotherapy (82 percent) were stratified into threesubgroups according to the age and leukocyte count at the timeof diagnosis: those with the best prognosis (a leukocyte countof less than 50,000 per cubic millimeter and an age of lessthan 10 years; 95 patients); those with an intermediate prognosis(intermediate-risk features; 92 patients); and those with theworst prognosis (a leukocyte count of more than 100,000 percubic millimeter; 80 patients). The estimates of disease-freesurvival at five years (±SE) were 49±5 percent(for patients with the best prognosis), 30±5 percent(for those with an intermediate prognosis), and 20±5percent (for those with the worst prognosis) (P<0.001 forthe overall comparison). We also found that transplantationof bone marrow from an HLA-matched related donor offered significantlygreater benefit than intensive chemotherapy alone in terms ofprotecting patients from relapse or other adverse events (relativerisk, 0.3; 95 percent confidence interval, 0.2 to 0.5; P<0.001).This finding was consistent in all three subgroups.
Conclusions Unlike the usual type of ALL, Ph-positive ALL isassociated with a poor prognosis. Nevertheless, in some patientswith favorable prognostic features, the disease can be controlledby intensive chemotherapy. Transplantation of bone marrow froman HLA-matched related donor is superior to other types of transplantationand to intensive chemotherapy alone in prolonging initial completeremissions.
Source Information
From the Department of Pediatrics, Istituto Ricovero e Cura a Carattere Scientifico, Policlinico San Matteo, Pavia, Italy (M.A.); the Department of Public Health, University of Verona, Verona, Italy (M.G.V.); the Department of Pediatrics, Midwest Children's Cancer Center, Medical College of Wisconsin, Milwaukee (B.C.); the Department of Pediatric HematologyOncology, Medizinische Hochschule, Hannover, Germany (M.S.); the Leukemia Research Fund, HematologyOncology, Institute of Child Health, London (J.C.); Service de Pédiatrie Hématologique, Hôpital Saint Louis, Paris (A.B.); Children's Hospital of Los Angeles and University of Southern California, Los Angeles (P.G.); the Department of Pediatric Oncology, DanaFarber Cancer Institute and Harvard Medical School, Boston (L.S.); the Department of Pediatric Hematology and Oncology, University of Hamburg, Hamburg, Germany (G.J.-S.); the Department of Pediatric Oncology, Beatrix Children's Hospital, Groningen, the Netherlands (W.K.); St. Jude Children's Research Hospital and the University of Tennessee College of Medicine, Memphis (C.-H.P.); and the Department of Pediatrics, University of Milan and Ospedale San Gerardo, Monza, Italy (G.M.). Other authors were V. Conter, M.D. (Associazione Italiana di Ematologia ed Oncologia Pediatrica); H. Riehm, M.D. (BerlinFrankfurtMünster Study Group); N. Heerema, Ph.D. (Children's Cancer Group); S. Sallan, M.D. (DanaFarber Cancer Institute, Boston); M.-F. Auclerc, M.D. (French Acute Lymphoblastic Leukemia Study Group); J. Pullen, M.D., J. Shuster, Ph.D., and A. Carroll, Ph.D. (Pediatric Oncology Group); S. Raimondi, Ph.D. (St. Jude Children's Research Hospital, Memphis, Tenn.); and S. Richards, M.D. (Medical Research Council, United Kingdom Acute Lymphoblastic Leukaemia).
Address reprint requests to Dr. Aricò at the Clinica Pediatrica, IRCCS Policlinico San Matteo, 27100 Pavia, Italy, or at aricom{at}unipv.it.
Fielding, A. K.
(2010). Current treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. haematol
95: 8-12
[Full Text]
Fisher, M. A., Beeson, D. C., Hans, M. G.
(2009). Dental Practice Network of U.S. Dental Schools. J Dent Educ
73: 1387-1393
[Abstract][Full Text]
Raponi, S., De Propris, M. S., Wai, H., Intoppa, S., Elia, L., Diverio, D., Vitale, A., Foa, R., Guarini, A.
(2009). An accurate and rapid flow cytometric diagnosis of BCR-ABL positive acute lymphoblastic leukemia. haematol
94: 1767-1770
[Abstract][Full Text]
Li, Z., Zhang, W., Wu, M., Zhu, S., Gao, C., Sun, L., Zhang, R., Qiao, N., Xue, H., Hu, Y., Bao, S., Zheng, H., Han, J.-D. J.
(2009). Gene expression-based classification and regulatory networks of pediatric acute lymphoblastic leukemia. Blood
114: 4486-4493
[Abstract][Full Text]
Schultz, K. R., Bowman, W. P., Aledo, A., Slayton, W. B., Sather, H., Devidas, M., Wang, C., Davies, S. M., Gaynon, P. S., Trigg, M., Rutledge, R., Burden, L., Jorstad, D., Carroll, A., Heerema, N. A., Winick, N., Borowitz, M. J., Hunger, S. P., Carroll, W. L., Camitta, B.
(2009). Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. JCO
27: 5175-5181
[Abstract][Full Text]
Pui, C.-H.
(2009). Toward a Total Cure for Acute Lymphoblastic Leukemia. JCO
27: 5121-5123
[Full Text]
Pulte, D., Gondos, A., Brenner, H.
(2009). Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century. Blood
113: 1408-1411
[Abstract][Full Text]
Schrappe, M.
(2008). Risk-adapted stratification and treatment of childhood acute lymphoblastic leukaemia. Radiat Prot Dosimetry
132: 130-133
[Abstract][Full Text]
Williams, R.T., Sherr, C.J.
(2008). The INK4-ARF (CDKN2A/B) Locus in Hematopoiesis and BCR-ABL-induced Leukemias. Cold Spring Harb Symp Quant Biol
0: sqb.2008.73.039v2-sqb.2008.73.039
[Abstract]
AricA{superscript 2}, M., Schrappe, M., Hunger, S., Carroll, W. L., Conter, V., Di Lorenzo, P., Manabe, A., Saha, V., Baruchel, A., Vettenranta, K., Tsuchida, M., Benoit, Y., Pieters, R., Escherich, G., Silverman, L. B., Pui, C.-H., Valsecchi, M. G.
(2008). Clinical Outcome of 640 Children with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated Between 1995 and 2005. ASH ANNUAL MEETING ABSTRACTS
112: 568-568
[Abstract]
Tucci, F., Arico, M.
(2008). Treatment of pediatric acute lymphoblastic leukemia. haematol
93: 1124-1128
[Full Text]
Mullighan, C. G., Williams, R. T., Downing, J. R., Sherr, C. J.
(2008). Failure of CDKN2A/B (INK4A/B-ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL. Genes Dev.
22: 1411-1415
[Abstract][Full Text]
Oudot, C., Auclerc, M.-F., Levy, V., Porcher, R., Piguet, C., Perel, Y., Gandemer, V., Debre, M., Vermylen, C., Pautard, B., Berger, C., Schmitt, C., Leblanc, T., Cayuela, J.-M., Socie, G., Michel, G., Leverger, G., Baruchel, A.
(2008). Prognostic Factors for Leukemic Induction Failure in Children With Acute Lymphoblastic Leukemia and Outcome After Salvage Therapy: The FRALLE 93 Study. JCO
26: 1496-1503
[Abstract][Full Text]
Fuster, J. L., Bermudez, M., Galera, A., Llinares, M. E., Calle, D., Ortuno, F. J.
(2007). Imatinib mesylate in combination with chemotherapy in four children with de novo and advanced stage Philadelphia chromosome-positive acute lymphoblastic leukemia. haematol
92: 1723-1724
[Abstract][Full Text]
Iori, A. P., Arcese, W., Milano, F., Calabrese, E., Torelli, G. F., Barberi, W., Mascolo, M. G., De Felice, L., Screnci, M., Lucarelli, B., Malandruccolo, L., Perrone, M. P., Salvatori, S., Laurenti, L., Iannella, E., Ricci, R., Moleti, M. L., Foa, R.
(2007). Unrelated cord blood transplant in children with high-risk acute lymphoblastic leukemia: a long-term follow-up. haematol
92: 1051-1058
[Abstract][Full Text]
Ribera, J.-M., Ortega, J.-J., Oriol, A.
(2007). In Reply. JCO
25: 2627-2628
[Full Text]
Feldhahn, N., Henke, N., Melchior, K., Duy, C., Soh, B. N., Klein, F., von Levetzow, G., Giebel, B., Li, A., Hofmann, W.-K., Jumaa, H., Muschen, M.
(2007). Activation-induced cytidine deaminase acts as a mutator in BCR-ABL1-transformed acute lymphoblastic leukemia cells. JEM
204: 1157-1166
[Abstract][Full Text]
Fujii, H., Trudeau, J. D., Teachey, D. T., Fish, J. D., Grupp, S. A., Schultz, K. R., Reid, G. S. D.
(2007). In vivo control of acute lymphoblastic leukemia by immunostimulatory CpG oligonucleotides. Blood
109: 2008-2013
[Abstract][Full Text]
Schultz, K. R., Pullen, D. J., Sather, H. N., Shuster, J. J., Devidas, M., Borowitz, M. J., Carroll, A. J., Heerema, N. A., Rubnitz, J. E., Loh, M. L., Raetz, E. A., Winick, N. J., Hunger, S. P., Carroll, W. L., Gaynon, P. S., Camitta, B. M.
(2007). Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood
109: 926-935
[Abstract][Full Text]
Choi, J., Hwang, Y. K., Sung, K. W., Lee, S. H., Yoo, K. H., Jung, H. L., Koo, H. H., Kim, H.-J., Kang, H. J., Shin, H. Y., Ahn, H. S.
(2007). Expression of Livin, an antiapoptotic protein, is an independent favorable prognostic factor in childhood acute lymphoblastic leukemia. Blood
109: 471-477
[Abstract][Full Text]
Ribera, J.-M., Ortega, J.-J., Oriol, A., Bastida, P., Calvo, C., Perez-Hurtado, J.-M., Gonzalez-Valentin, M.-E., Martin-Reina, V., Molines, A., Ortega-Rivas, F., Moreno, M.-J., Rivas, C., Egurbide, I., Heras, I., Poderos, C., Martinez-Revuelta, E., Guinea, J.-M., del Potro, E., Deben, G.
(2007). Comparison of Intensive Chemotherapy, Allogeneic, or Autologous Stem-Cell Transplantation As Postremission Treatment for Children With Very High Risk Acute Lymphoblastic Leukemia: PETHEMA ALL-93 Trial. JCO
25: 16-24
[Abstract][Full Text]
Schrauder, A., Reiter, A., Gadner, H., Niethammer, D., Klingebiel, T., Kremens, B., Peters, C., Ebell, W., Zimmermann, M., Niggli, F., Ludwig, W.-D., Riehm, H., Welte, K., Schrappe, M.
(2006). Superiority of Allogeneic Hematopoietic Stem-Cell Transplantation Compared With Chemotherapy Alone in High-Risk Childhood T-Cell Acute Lymphoblastic Leukemia: Results From ALL-BFM 90 and 95. JCO
24: 5742-5749
[Abstract][Full Text]
Meshinchi, S., Arceci, R. J., Sanders, J. E., Smith, F. O., Woods, W. B., Radich, J. P., Alonzo, T. A., Gale, R. E., Hills, R., Wheatley, K., Burnett, A. K., Linch, D. C.
(2006). Role of allogeneic stem cell transplantation in FLT3/ITD-positive AML.. Blood
108: 400-401
[Full Text]
Coustan-Smith, E., Ribeiro, R. C., Stow, P., Zhou, Y., Pui, C.-H., Rivera, G. K., Pedrosa, F., Campana, D.
(2006). A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome. Blood
108: 97-102
[Abstract][Full Text]
Loh, M. L., Goldwasser, M. A., Silverman, L. B., Poon, W.-M., Vattikuti, S., Cardoso, A., Neuberg, D. S., Shannon, K. M., Sallan, S. E., Gilliland, D. G.
(2006). Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01. Blood
107: 4508-4513
[Abstract][Full Text]
Pui, C.-H., Evans, W. E.
(2006). Treatment of Acute Lymphoblastic Leukemia. NEJM
354: 166-178
[Full Text]
Armstrong, S. A., Look, A. T.
(2005). Molecular Genetics of Acute Lymphoblastic Leukemia. JCO
23: 6306-6315
[Abstract][Full Text]
Zhang, B., Groffen, J., Heisterkamp, N.
(2005). Resistance to farnesyltransferase inhibitors in Bcr/Abl-positive lymphoblastic leukemia by increased expression of a novel ABC transporter homolog ATP11a. Blood
106: 1355-1361
[Abstract][Full Text]
Hotfilder, M., Rottgers, S., Rosemann, A., Schrauder, A., Schrappe, M., Pieters, R., Jurgens, H., Harbott, J., Vormoor, J.
(2005). Leukemic Stem Cells in Childhood High-Risk ALL/t(9;22) and t(4;11) Are Present in Primitive Lymphoid-Restricted CD34+CD19- Cells. Cancer Res.
65: 1442-1449
[Abstract][Full Text]
Gutierrez, M. I., Timson, G., Siraj, A. K., Bu, R., Barbhaya, S., Banavali, S., Bhatia, K.
(2005). Single Monochrome Real-Time RT-PCR Assay for Identification, Quantification, and Breakpoint Cluster Region Determination of t(9;22) Transcripts. J. Mol. Diagn.
7: 40-47
[Abstract][Full Text]
Hunault, M., Harousseau, J.-L., Delain, M., Truchan-Graczyk, M., Cahn, J.-Y., Witz, F., Lamy, T., Pignon, B., Jouet, J.-P., Garidi, R., Caillot, D., Berthou, C., Guyotat, D., Sadoun, A., Sotto, J.-J., Lioure, B., Casassus, P., Solal-Celigny, P., Stalnikiewicz, L., Audhuy, B., Blanchet, O., Baranger, L., Bene, M.-C., Ifrah, N., for the GOELAMS (Groupe Ouest-Est des Leucemies Ai,
(2004). Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. Blood
104: 3028-3037
[Abstract][Full Text]
Champagne, M. A., Capdeville, R., Krailo, M., Qu, W., Peng, B., Rosamilia, M., Therrien, M., Zoellner, U., Blaney, S. M., Bernstein, M.
(2004). Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study. Blood
104: 2655-2660
[Abstract][Full Text]
Lee, J., Sait, S. N., Wetzler, M.
(2004). Characterization of dendritic-like cells derived from t(9;22) acute lymphoblastic leukemia blasts. Int Immunol
16: 1377-1389
[Abstract][Full Text]
Harata, M., Soda, Y., Tani, K., Ooi, J., Takizawa, T., Chen, M., Bai, Y., Izawa, K., Kobayashi, S., Tomonari, A., Nagamura, F., Takahashi, S., Uchimaru, K., Iseki, T., Tsuji, T., Takahashi, T. A., Sugita, K., Nakazawa, S., Tojo, A., Maruyama, K., Asano, S.
(2004). CD19-targeting liposomes containing imatinib efficiently kill Philadelphia chromosome-positive acute lymphoblastic leukemia cells. Blood
104: 1442-1449
[Abstract][Full Text]
Soda, Y., Tani, K., Bai, Y., Saiki, M., Chen, M., Izawa, K., Kobayashi, S., Takahashi, S., Uchimaru, K., Kuwabara, T., Warashina, M., Tanabe, T., Miyoshi, H., Sugita, K., Nakazawa, S., Tojo, A., Taira, K., Asano, S.
(2004). A novel maxizyme vector targeting a bcr-abl fusion gene induced specific cell death in Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood
104: 356-363
[Abstract][Full Text]
Thomas, D. A., Faderl, S., Cortes, J., O'Brien, S., Giles, F. J., Kornblau, S. M., Garcia-Manero, G., Keating, M. J., Andreeff, M., Jeha, S., Beran, M., Verstovsek, S., Pierce, S., Letvak, L., Salvado, A., Champlin, R., Talpaz, M., Kantarjian, H.
(2004). Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood
103: 4396-4407
[Abstract][Full Text]
Pui, C.-H., Relling, M. V., Downing, J. R.
(2004). Acute Lymphoblastic Leukemia. NEJM
350: 1535-1548
[Full Text]
Fine, B. M., Stanulla, M., Schrappe, M., Ho, M., Viehmann, S., Harbott, J., Boxer, L. M.
(2004). Gene expression patterns associated with recurrent chromosomal translocations in acute lymphoblastic leukemia. Blood
103: 1043-1049
[Abstract][Full Text]
Pui, C.-H., Schrappe, M., Ribeiro, R. C., Niemeyer, C. M.
(2004). Childhood and Adolescent Lymphoid and Myeloid Leukemia. ASH Education Book
2004: 118-145
[Abstract][Full Text]
Carroll, W. L.
(2003). Race and Outcome in Childhood Acute Lymphoblastic Leukemia. JAMA
290: 2061-2063
[Full Text]
Kochling, J., Konig-Merediz, S. A., Stripecke, R., Buchwald, D., Korte, A., von Einsiedel, H. G., Sack, F., Henze, G., Seeger, K., Wittig, B., Schmidt, M.
(2003). Protection of Mice against Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia by Cell-based Vaccination Using Nonviral, Minimalistic Expression Vectors and Immunomodulatory Oligonucleotides. Clin. Cancer Res.
9: 3142-3149
[Abstract][Full Text]
Marshall, G. M., Haber, M., Kwan, E., Zhu, L., Ferrara, D., Xue, C., Brisco, M. J., Sykes, P. J., Morley, A., Webster, B., Dalla Pozza, L., Waters, K., Norris, M. D.
(2003). Importance of Minimal Residual Disease Testing During the Second Year of Therapy for Children With Acute Lymphoblastic Leukemia. JCO
21: 704-709
[Abstract][Full Text]
Carroll, W. L., Bhojwani, D., Min, D.-J., Raetz, E., Relling, M., Davies, S., Downing, J. R., Willman, C. L., Reed, J. C.
(2003). Pediatric Acute Lymphoblastic Leukemia. ASH Education Book
2003: 102-131
[Abstract][Full Text]
Dombret, H., Gabert, J., Boiron, J.-M., Rigal-Huguet, F., Blaise, D., Thomas, X., Delannoy, A., Buzyn, A., Bilhou-Nabera, C., Cayuela, J.-M., Fenaux, P., Bourhis, J.-H., Fegueux, N., Charrin, C., Boucheix, C., Lheritier, V., Esperou, H., MacIntyre, E., Vernant, J.-P., Fiere, D.
(2002). Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia---results of the prospective multicenter LALA-94 trial. Blood
100: 2357-2366
[Abstract][Full Text]
Hotfilder, M., Rottgers, S., Rosemann, A., Jurgens, H., Harbott, J., Vormoor, J.
(2002). Immature CD34+CD19- progenitor/stem cells in TEL/AML1-positive acute lymphoblastic leukemia are genetically and functionally normal. Blood
100: 640-646
[Abstract][Full Text]
Willemse, M. J., Seriu, T., Hettinger, K., d'Aniello, E., Hop, W. C. J., Panzer-Grumayer, E. R., Biondi, A., Schrappe, M., Kamps, W. A., Masera, G., Gadner, H., Riehm, H., Bartram, C. R., van Dongen, J. J. M.
(2002). Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL. Blood
99: 4386-4393
[Abstract][Full Text]
Woolfrey, A. E., Anasetti, C., Storer, B., Doney, K., Milner, L. A., Sievers, E. L., Carpenter, P., Martin, P., Petersdorf, E., Appelbaum, F. R., Hansen, J. A., Sanders, J. E.
(2002). Factors associated with outcome after unrelated marrow transplantation for treatment of acute lymphoblastic leukemia in children. Blood
99: 2002-2008
[Abstract][Full Text]
Savage, D. G., Antman, K. H.
(2002). Imatinib Mesylate -- A New Oral Targeted Therapy. NEJM
346: 683-693
[Full Text]
Bickert, B. M.
(2002). Treatment of Common Childhood Malignancies. Journal of Pharmacy Practice
15: 42-51
[Abstract]
Annino, L., Vegna, M. L., Camera, A., Specchia, G., Visani, G., Fioritoni, G., Ferrara, F., Peta, A., Ciolli, S., Deplano, W., Fabbiano, F., Sica, S., Di Raimondo, F., Cascavilla, N., Tabilio, A., Leoni, P., Invernizzi, R., Baccarani, M., Rotoli, B., Amadori, S., Mandelli, F.
(2002). Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood
99: 863-871
[Abstract][Full Text]
Hoelzer, D., Gokbuget, N., Ottmann, O., Pui, C.-H., Relling, M. V., Appelbaum, F. R., van Dongen, J. J.M., Szczepanski, T.
(2002). Acute Lymphoblastic Leukemia. ASH Education Book
2002: 162-192
[Abstract][Full Text]
Kudoh, T., Suzuki, N., Hatakeyama, N., Mizue, N., Hori, T., Oda, T., Watanabe, J., Imamura, M., Chiba, S.
(2001). Successful Unrelated Cord Blood Transplantation in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia During Pulmonary Aspergillosis Treated by Anti-fungal Therapy, Granulocyte Colony-stimulating Factor-mobilized Granulocytes and Surgical Resection: Case Report. Jpn J Clin Oncol
31: 290-293
[Abstract][Full Text]
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., Talpaz, M.
(2001). Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome. NEJM
344: 1038-1042
[Abstract][Full Text]
Cornelissen, J. J., Carston, M., Kollman, C., King, R., Dekker, A. W., Lowenberg, B., Anasetti, C.
(2001). Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. Blood
97: 1572-1577
[Abstract][Full Text]
Oki, Y., Kishi, Y., Kami, M., Fruchter, O., Valsecchi, M. G., Schrappe, M., Pui, C.-H.
(2000). Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Children. NEJM
343: 1043-1044
[Full Text]
Felix, C. A., Lange, B. J., Chessells, J. M.
(2000). Pediatric Acute Lymphoblastic Leukemia: Challenges and Controversies in 2000. ASH Education Book
2000: 285-302
[Abstract][Full Text]